Biogen Inc

BIIBNASDAQ · USD
249.59USD0.00 (+1.00%)
6310

Biogen Inc (BIIB) Option Chain

Biogen Inc trades at $249.59, up 1.00%, with an IV Rank of 100.00%. This is high versus the past year, and the company carries a market cap of $36,894M in the Drug Manufacturers - General industry. On the Nov 27, 2026 chain, the at the money $250.00 strike shows calls at $3.60 / $6.70 and puts at $3.30 / $6.40, both carrying about $4.80 of extrinsic value. The call has a 52.07% probability of expiring out of the money, and the put has 47.93%. Volume is heaviest on the $300.00 calls, at 240 contracts, and the $230.00 puts, at 100, as of Nov 20, 2026.

Read more

Tracking the BIIB option chain helps you see every strike and expiry on Biogen Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of BIIB options activity at a glance. Use our scanner to monitor the BIIB option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For BIIB stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where BIIB options are being actively traded, and where they are not.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.

2026-11-27
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
42.38213.264.596.309.40245.00-1.842.053.500.002.7851157.62
47.23004.262.094.708.00247.50-0.842.055.300.003.68025152.77
52.076105.150.003.606.70250.00+0.163.306.400.414.44222147.93
56.844914.000.002.405.60252.50+1.174.607.802.913.2902643.16
61.462112.900.002.203.60255.00+2.176.209.405.412.3901338.54

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - General
  • SectorHealthcare
  • IV Rank100.00% High
  • Market cap (M$)36,894
  • 52 weeks high-4.37%
  • 52 weeks low55.64%
  • Analyst recommendationBuy
    1.86
  • Target price$271.69
    8.85% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2027-02-05
  • P/E106.85
  • Future P/E15.40
  • EPS (ttm)2.34
  • EPS growth next 5 years6.41%

As of Nov 20, 2026